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Sabrina Röttger-Wirtz*
When it comes to the question of transparency and
access to documents, the European Medicines
Agency finds itself between a rock and a hard place.
In the past the EMA has been criticized, for example
by the European Ombudsman,1 for not being trans-
parent enough and excessively redacting documents
requested especially with regard to potentially com-
mercially confidential information. The pharma in-
dustry on the other hand, has now repeatedly taken
the Agency to Court for granting third parties access
to documents they submitted to the EMA, claiming
an infringement of their rights to protection of com-
mercially confidential information. While cases
brought in 2013 by AbbVie and InterMune ended
with anout of court settlement,2uncertainty remains
regarding the scope of the protection of commercial
interests against publication under Article 4(2) of
Regulation 1049/2011 (‘Transparency Regulation’).
Article 4(2) of Regulation 1049/2011 forms an ex-
ception to the right of access to documents for specif-
ic reasons, such as ‘commercial interests of a natural
or legal person, including intellectual property’, with-
out defining these protected commercial interests fur-
ther. Therefore, as the EMA has to apply the Trans-
parencyRegulation,3 theAgencywas left to define the
scope of this exception in its ownaccess to documents
policy,4 exposing it to the criticism of being either too
transparent or too protective of commercial interest.
This apparently difficult balance between trans-
parency as a core value of European law, enshrined
in Article 15 TFEU, and the protection of commer-
cially sensitive information, is by no means a chal-
lenge that is unique to the pharmaceutical sector, as
the debate surrounding access to documents for the
glyphosate re-authorization shows.5 However, three
cases ruled by the General Court in February have
nowclarified somequestions on thebalancebetween
transparency and commercially confidential infor-
mation. It should be noted that in the PTC case and
the Intervet case appeals have been filed.
DOI: 10.21552/eplr/2018/2/9
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1 See eg European Ombudsman, ‘Decision of the European
Ombudsman closing his inquiry into complaint 2560/2007/BEH
against the European Medicines Agency’ (November 2010);
European Ombudsman, ‘Decision on own-initiative inquiry
OI/3/2014/FOR concerning the partial refusal of the European
Medicines Agency to give public access to studies related to the
approval of a medicinal product’ (June 2016). It should be
noted in this regard, that in recent cases the Ombudsman has
taken a very positive view of the current EMA access to docu-
ments policy and the proactive publication of clinical trials, see
European Ombudsman, ‘Decision in case 1602/2016/JAS on
the European Medicines Agency’s handling of an access to
document request related to clinical study report’ (February
2018).
2 The General Court had annulled the interim measures which
stopped the EMA from releasing the documents in question: Case
C-390/13 P(R) EMA v InterMune UK and Others [2013]
ECLI:EU:C:2013:795; C-389/13 P(R) EMA v AbbVie [2013]
ECLI:EU:C:2013:794.
3 Art 73 of Regulation (EC) No 726/2004 foresees that Regulation
(EC) No 1049/2001 applies to the Agency.
4 Currently applicable EMA access to documents policy: EMA,
‘European Medicines Agency policy on access to documents
(related to medicinal products for human and veterinary use)’
(2010) EMA/110196/2006.
5 In a previous issue of the EPLR, Giulia Schneider discussed this
balance: Giulia Schneider, ‘A Transparency Challenge: Can
Commercial Confidentiality In Clinical Trials Data Be Overcome?’
(2018) European Pharmaceutical Law Review 2(1), 3-18. For a
detailed account of the debate surrounding Glyphosate see: E
Korkea-aho and P Leino, ‘Who owns the information held by EU
Agencies? Weed killers, commercially sensitive information and
transparent and participatory governance’ (2017) Common Mar-
ket Law Review 54 (4) 1059 -1092.
EPLR 2|2018 109Case Notes
I. The Facts and Dispute in the Main
Proceedings
In all three cases at hand, access to documents re-
quest had been addressed to the EuropeanMedicines
Agency by a competitor company, requesting access
to documents submitted to the EMAby another com-
pany - a third party in terms of the access to docu-
ments request - in the course of a marketing autho-
rization procedure.
In the PTC Therapeutics case (T-718/15) the docu-
ment concerned was a clinical study report submit-
ted in the marketing authorization procedure for
Translarna. While in theMSD Animal Health and In-
tervet case (T-729/15) a competitor requested access
to toxicology tests submitted in the course of themar-
keting authorization procedure for the veterinary
medicine Bravecto.
In the Pari Pharma case (T-235/15) the factual
background is a bitmore complex. The access to doc-
uments request concerned similarity and superiori-
ty reports with regard to an orphan medicinal prod-
uct. In the case at hand, Novartis was the holder of
a marketing authorization for TOBI as well as the or-
phan medicinal product TOBI podhaler, the orphan
status of the latter beingbasedon the significant ben-
efits to the patients when compared to the existing
treatment. Pari Pharma requested a marketing au-
thorization for Vantobra with the same therapeutic
indication as TOBI podhaler. Due to the orphan sta-
tus of TOBI podhaler, amarketing authorizationwas
only granted where similarity and clinical superior-
ity of Vantobra could be shown. Vantobra was found
to fulfil these conditions and was grantedmarketing
authorization. The application was a hybrid applica-
tion under Article 10(3), relying partially on docu-
mentation provided for TOBI. In the access to docu-
ments request Novartis asked for access to the mar-
keting authorization report of Vantobra. Novartis
had challenged the Vantobra marketing authoriza-
tion.
The core question the EMA had to decide upon
when receiving the access to documents requestswas
the applicability of the exception in Article 4(2) of
the Transparency Regulation:
‘The institutions shall refuse access to a document
where disclosure would undermine the protection
of: (…) commercial interests of a natural or legal per-
son, including intellectual property (…) unless there
is an overriding public interest in disclosure.’
Moreover, the exception in Article 4(3) applicable
to documents in an un-finished procedure within an
EU institution could also have been relevant, as for
example in the PTC casewhere the product to which
the documents related had been granted a condition-
al marketing authorization.
In all of these cases, upon receipt of the request
for access to documents, the EMA had informed the
companies which had originally submitted the doc-
uments (the ‘thirdparties’ in the access to documents
procedure) of the access requests in accordance with
its access to documents policy (Policy 0043).6When
the EMA receives such access to documents request,
Article 4(4) of the Transparency Regulation pre-
scribes that the third party has to be consulted on
the applicability of the exceptions to access, unless
it is already clear for the institution that the docu-
ment will be disclosed or will definitely not be dis-
closed. If the applicability or non-applicability of an
exception is not obvious to the Agency, the compa-
ny that submitted the document in the first place
will be consulted, which usually includes being al-
lowed to submit a redacted version.7 The request not
to disclose by the third party does not bind the
agency, but in case the EMA will publish against the
will of the third party, the third party will be notified
of this before, with mention of the option for reme-
dies.8
In the cases at hand, the EMA and the companies
which had submitted the documents in question dis-
agreed about the necessity and extent of redactions.
This led to interim relief procedures in all three cas-
es, in which the General Court suspended the EMA’s
decisions to disclose the documents in question.9
6 EMA, ‘European Medicines Agency policy on access to docu-
ments (related to medicinal products for human and veterinary
use)’ (2010) EMA/110196/2006.
7 ibid 4-5; EMA, Rules for the implementation of Regulation (EC)
No 1049/2001 on access to EMA documents, Management Board
meeting 19 December 2006, EMEA/MB/203359/2006 Rev 1
Adopted, art 8.
8 Rules for the implementation of Regulation (EC) No 1049/2001
on access to EMEA documents, Management Board meeting 19
December 2006, EMEA/MB/203359/2006 Rev 1 Adopted, art
8(7).
9 Case T-235/15 Pari Pharma v EMA [2015] ECLI:EU:T:2015:587
and Pari Pharma v EMA [2016] ECLI:EU:T:2016:309; T-718/15
PTC Therapeutics International v EMA [2016]
ECLI:EU:T:2016:425; T-729/15 MSD Animal Health Innovation
and Intervet international v EMA [2016] ECLI:EU:T:2016:435.
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The cases on the merits of these claims in front
the General Court all dealt with a similar set of argu-
ments. This case note will focus on the following
claims:
– the documents in question are protected by Arti-
cle 4(2) or (3) ofRegulationNo 1049/2001 pursuant
to a general presumption of confidentiality;
– the documents in question are in their entirety
commercially confidential information and are
protected by Article 4(2) or (3) of Regulation No
1049/2001;
– parts of documents in question are commercially
confidential information protected by Article 4(2)
or (3) of Regulation No 1049/2001.
II. Judgment of the Court
1. Are the Documents in Question
Protected by Article 4(2) or (3) of
Regulation No 1049/2001 Pursuant to
a General Presumption of
Confidentiality?
The Court decided to first deal with the question of
whether documents submitted in the context of a
marketing authorization procedure, and essentially
the whole Committee report, could benefit from a
general presumption of confidentiality based on the
protection of commercial interests in Article 4(2) or
4(3) of Regulation No 1049/2001. Pari Pharma for ex-
ample argued that: ‘(…) protection of confidentiality
should not only extend to the parts of the reports
containing the most sensitive confidential informa-
tion, but to the reports as such, because themost sen-
sitive parts are integrated in a line of arguments
which include matters relating to its proprietary
strategy, and which formwith other public elements
of the reports an inseparable whole with economic
value.’10
However, such a presumption of confidentiality
would constitute a considerable interferencewith the
principle of widest possible access to documents en-
shrined in the Transparency Regulation. Therefore,
it is not surprising that according to the Court such
an exemption will have to be narrowly construed.
The Court, assessing previous cases, where such a
general presumption of confidentiality for certain
types of documentshadbeenaccepted, however, con-
cluded that all of these categories of documents
awarded a general presumption of confidentiality
were part of an ongoing administrative or judicial
procedure.11 As the marketing authorization proce-
dures of the respective products for which the access
to documents was requested in the three cases were
concluded, they could not avail themselves of the ex-
ception of ongoing administrative procedures.12 The
fact that in the PTC case themarketing authorization
granted was a conditional marketing authorization
did not matter in this regard.13 The Court ruled in all
three cases that once the administrative proceedings
of a marketing authorization application have been
finalized, the reports drawn up by the Agencies' sci-
entific committees, containing all the documents
concerned in the cases, are not subject to a general
presumption of confidentiality.
In this regard, the Court also specifically refused
an argument based on Article 39 of the TRIPS agree-
ment. In the Intervet case and the PTC case the ap-
plicants argued that the documents are covered by a
presumption of confidentiality throughout the peri-
od of data exclusivity ormarket exclusivity of orphan
medicinal products, to prevent third parties from
submitting this datawith anewmarketing authoriza-
tion application. The Court had already stated that a
possible reuse of the data concerned ‘does not, in it-
self, constitute a ground to consider that the infor-
mation is confidential’, but that commercial confi-
dentiality can and has to be proven for specific parts
of the document.14 According to the Court, also the
applicability of Article 39(2) and (3) of the TRIPS
Agreement do not lead to a presumption of confiden-
tially during the data exclusivity period or the mar-
ket exclusivity period grated to orphan medicinal
products.15 The Court in this regard implies that the
European framework under Regulation 1049/2001
and 736/2004 sufficiently protects the data against
unfair commercial use in the sense of the TRIPS
10 Case T-235/15 Pari Pharma GmbH v European Medicines Agency
[2018] ECLI:EU:T:2018:65, para 36.
11 ibid, para 46.
12 ibid, para 57.
13 Case T-718/15 PTC Therapeutics International Ltd v European
Medicines Agency [2018] ECLI:EU:T:2018:66, para 74.
14 Case T-729/15 MSD Animal Health Innovation GmbH and
Intervet international BV v European Medicines Agency [2018]
ECLI:EU:T:2018:67, para 46.
15 ibid, para 50; Case T-718/15 PTC Therapeutics International Ltd v
European Medicines Agency [2018] ECLI:EU:T:2018:66, para 64.
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agreement.16 In this regard, it should also be men-
tioned that the Court rejected an argument based on
the possibility that data could be used in third coun-
tries to obtain marketing authorizations. The Court
argued that as sensitive data such as the method for
drug concentration measurement do remain confi-
dential, no proof was provided that the use of the da-
ta in third countries is actually a risk.17
As all arguments in this claim failed, a general pre-
sumption of confidentiality for committee reports
and all contained documents does not exist once the
marketing authorization procedure is finalized.
2. Are the Documents in Question in
their Entirety Commercially
Confidential Information and subject
to the exception under Article 4(2) or
(3) of Regulation No 1049/2001?
Although, in the absence of a general presumption
of confidentiality, the EMA will thus have to carry
out an individual assessment of each document to
which access is requested, the documents in question
could still be commercially sensitive in their entire-
ty. However, none of the applicants could convince
the Court in this regard.
In principle, the Court did not exclude that the
whole report could constitute commercially sensi-
tive information. However, this would have to be
specifically proven. The bottom line of the Courts
approach is best to be explained by a quote from the
PTC case:
‘Consequently, in order to be able to claim confi-
dential treatment in respect of the entire report at
issue, it is for the applicant to show that the as-
sembly of the publicly-accessible data together
with the data which is not publicly accessible con-
stitutes a commercially sensitive item of data
whose disclosure would undermine its commer-
cial interests. The assertion that ‘thewhole ismore
than the sum of its parts’ is too vague to show that
that assembly of information could produce the
consequences alleged. It was all the more neces-
sary to adduce precise and proper explanations
since, as has been pointed out in paragraph 80
above, the exceptions provided for in Article 4 of
Regulation No 1049/2001 derogate from the prin-
ciple that the public should have the widest possi-
ble access to the documents andmust therefore be
interpreted and applied strictly.’18
Thus, where the entirety of a document should
benefit from the exception under Article 4 of the
Transparency Regulation, the congregation of the
(non-protected) information as such must have com-
mercial value.
3. Are Parts of Documents in Question
Commercially Confidential
Information Protected by Article 4(2)
or (3) of Regulation No 1049/2001?
As the arguments for the applicability of the excep-
tions for the entirety of the reports failed, the appli-
cants argued for protection of parts of the documents
in question. Again, in all three cases the respective
arguments failed. Rather than looking at the individ-
ual reasons for denying the applicants the protection
they sought under Article 4(2) and (3) of the Trans-
parency Regulation, the following section will exam-
ine how the Court constructs the requirements of the
Article to exempt commercially sensitive informa-
tion from thegeneral rule that access shouldbegrant-
ed.
First of all, relying on case law such as case
T-437/08 Hydorgene Peroxide v Commission and case
T-516/11 MasterCard and others v Commission, the
Court makes clear that commercially sensitive infor-
mation is not simply any information about a com-
pany or its business relations,19 the hurdle to com-
mand protection from publication under Article 4(2)
of the Transparency Regulation is higher. According
to the Court, what is required for a correct applica-
tion of the exception is that the access to that docu-
ment could ‘specifically and actually undermine the
16 Case T-729/15 MSD Animal Health Innovation GmbH and
Intervet international BV v European Medicines Agency [2018]
ECLI:EU:T:2018:67, para 51; Case T-718/15 PTC Therapeutics
International Ltd v European Medicines Agency [2018]
ECLI:EU:T:2018:66, para 65; See also in this regard, Giulia Sch-
neider, ‘A Transparency Challenge: Can Commercial Confidential-
ity In Clinical Trials Data Be Overcome?’ (2018) European Phar-
maceutical Law Review 2(1), 3-18.
17 Case T-718/15 PTC Therapeutics International Ltd v European
Medicines Agency [2018] ECLI:EU:T:2018:66, para 94.
18 ibid para 89.
19 Case T-235/15 Pari Pharma GmbH v European Medicines Agency
[2018] ECLI:EU:T:2018:65, para 70.
EPLR 2|2018112 Case Notes
interest protected by an exception laid down in that
article’.20 This means that, ‘it must be shown that the
documents at issue contain elements which may, if
disclosed, seriously undermine the commercial inter-
estof a legalperson’,21which includesbusiness strate-
gies or ‘information particular to that undertaking
which reveals its expertise’.22
Merely compiling publicly available studies or sci-
entific reports will not satisfy this hurdle, whereas
adding value to such data by drawing novel scientif-
ic conclusions or developing an inventive strategy
can satisfy the conditions.23 An argument that the
Court was quite clear about in these cases was that
the documents in question failed to show a know-
how or novelty in approach regarding how the stud-
ies in question were conducted, regarding ‘models,
assays or methodologies’.24 In the Intervet case, for
example, the applicant claimed that the study reports
in question would be commercially sensitive as they
are based on significant regulatory knowledge and
strategic approaches to innovative study design.25
The EMA countered this argument by referring to
the EU and international guidelines and recommen-
dations that form the basis of the safety tests.26 Ac-
cording to the Court, ‘the applicants have not put for-
ward any scientific evidence to show that the reports
contain any elements that are unique and important
for informing their overall strategy and development
programme.’27 It should also be mentioned that the
significant costs involved in actually conducting the
studies did not satisfy the Court, as these costs are
incurred by all pharmaceutical undertakings.28
III. Comment
Although the outcome of these rulings will certainly
not be welcomed by everyone, at least they provide
some clarity in a situation of uncertainty that has
kept the pharmaceutical industry as well as the EMA
busy since several years.
1. Do the Judgements Clarify the Scope
of Commercial Confidentiality in
Terms of Article 4(2) and (3) of the
Transparency Regulation?
The Court approached the question of commercial-
ly sensitive information from a more abstract stand-
point. It did not provide too much guidance on what
actually constitutes commercially confidential infor-
mation in the marketing authorization documenta-
tion, but focused on requiring that each and every
individual claim of commercially sensitive informa-
tion of a document or its parts has to be well sub-
stantiated with very concrete proof in order to suc-
cessfully avail itself of the application of the excep-
tion in Article 4(2) and (3) of the Transparency Reg-
ulation. What these judgements have made very
clear, is that the age of broad and unsubstantiated
claims to commercial confidentiality is over. While
the Court does not generally exclude protection un-
der the exception for any of the documents in ques-
tion, it has made very clear that any application of
this exception to the general rule of transparency has
to be duly substantiated by scientific or economic ar-
guments of novelty, innovation and unique exper-
tise.
Reading the judgments, one cannot help but won-
der what will still fall under the protection of com-
mercially confidential information, as it is quite clear
that the hurdle to prove commercial confidentiality
is quite high. The judgements do not provide a clear
list of commercially confidential information, unlike
what the EMA and Heads of Medicines Agencies
(HMA) have provided in their respective policies,29
but focusses on an obligation to prove novelty and
uniqueness to invoke the exception.What thismeans
in practice is that the dispute betweenmarketing au-
thorization holders and the Agency will have to con-
20 ibid para 69.
21 ibid para 71.
22 ibid.
23 ibid para 77.
24 Case T-718/15 PTC Therapeutics International Ltd v European
Medicines Agency [2018] ECLI:EU:T:2018:66, para 90.
25 Case T-729/15 MSD Animal Health Innovation GmbH and
Intervet international BV v European Medicines Agency [2018]
ECLI:EU:T:2018:67, para 59.
26 ibid paras 72 and 73.
27 ibid para 75.
28 ibid para 89.
29 HMA/EMA, ‘Guidance Document on the Identification of com-
mercially confidential information and personal data within the
structure of the marketing authorization (MA) application –
Release of information after the granting of a marketing authoriza-
tion’ <http://www.ema.europa.eu/docs/en_GB/document_library/
Other/2012/03/WC500124536.pdf> accessed 21 April 2018;
EMA, ‘Principles to be applied for the deletion of commercially
confidential information for the disclosure of EMEA Documents’
(April 2007) EMEA/45422/2006.
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tinue, until the contours of sufficient prove for the
requirements developed for the applicability of the
exception are clearer.
2. What does this Mean for the Clinical
Trials Publication under EMA policy
0070 and the Clinical Trials Regulation?
Thepotential conflict between transparency andpro-
tection of commercial confidentiality is not only in-
herent in access to document request under the
TransparencyRegulation, but is also encompassed in
the proactive clinical trials data publication under
EMA policy 0070,30 as well as the Clinical Trials Reg-
ulation.31 In this regard, also Article 81(4)(b) of the
Clinical Trials Regulation contains an exception to
public access to clinical trials data on the basis of pro-
tection of commercially confidential information in
absence of an overriding reason of public interest in
disclosure.
An advice from the clinical trial advisory group on
legal aspects to the European Medicines from 2013
shows, the arguments pro and counter the proactive
publication of clinical trial data by the agency are
made along the same lines as the arguments in the
access to documents cases at hand.32 The General
Court, although ruling on access to documents cas-
es, has thereby confirmed the arguments for proac-
tive publication of clinical trials data. In policy 0070,
the factors on which the EMA decides on the com-
mercial sensitive of certain data are: ‘the nature of
the product concerned, the competitive situation of
the therapeutic market in question, the approval sta-
tus in other jurisdictions, the novelty of the clinical
development, and new developments by the same
company.’33 This seems to be largely congruent with
the Court rulings at hand and might already provide
some indications with regard to how pharma com-
panies might approach evidencing commercial sen-
sitive information.
However, similar to the access to documents re-
quest, we will probably continue to see debates be-
tween the Agency and the industry about the con-
crete applicationof the requirements ofproof of com-
mercial sensitivity also with regard to the proactive
publication of clinical trials data. The proactive pub-
lication process however, through the sheer mass of
data, will at first mean a labor-intensive process on
the side of both the Agency and the industry. How-
ever, itwill alsomean that further clarityon theEMAs
stance on what is commercially sensitive will devel-
op quicker.
3. Transparency in Pharma: A Normative
Choice
In the context of the debate surrounding transparen-
cy of clinical trials data and industry originating doc-
uments in general,manyargumentshavebeen raised
in favor and against publication.34 In all three cases
at hand here, the access to documents request was
filedbycompetitor companies.Onemight legitimate-
ly ask if this serves the promotion of public health.
Therefore, it makes sense to take a closer look at the
rationale of transparency in this context.
According to the EMA, as far as the proactive pub-
lication of clinical trial data is concerned, the objec-
tives of the policy are the facilitation of public scruti-
ny as well as ‘to make medicine development more
efficient by establishing a level playing field that al-
lows all medicine developers to learn from past suc-
cesses and failures’, both for the benefit of public
health.35 Thus, the argument is twofold: transparen-
cy of the data used in the marketing authorization
process is asmuch concernedwith the public control
over the EMA decision-making process as it is with
the promotion of health innovation.
If one were only concerned about the effect of
transparency on the development of new pharma-
ceuticals, the debate between pro- and counter- argu-
30 EMA, 'European Medicines Agency policy on publication of
clinical data for medicinal products for human use, POLI-
CY/0070' (October 2014) EMA/240810/2013.
31 Regulation (EU) No 536/2014 of the European Parliament and of
the Council of 16 April 2014 on clinical trials on medicinal
products for human use, and repealing Directive 2001/20/EC
[2014] OJ L 158, 1–76.
32 Clinical trial Advisory Group on Legal aspects (CAG5), ‘Final
advice to the European Medicines Agency from the clinical
trial advisory group on legal aspects’ (April 2013) <http://www
.ema.europa.eu/docs/en_GB/document_library/Other/2013/04/
WC500142857.pdf> accessed 10 May 2018.
33 EMA, ‘European Medicines Agency policy on publication of
clinical data for medicinal products for human use, POLI-
CY/0070’ (October 2014) EMA/240810/2013, 4.2.2.1.
34 See eg, H G Eichler amd E Abadie, A Breckenridge, H Leufkens
and G Rasi, ‘Open Clinical Trial Data for All? A View from Regu-
lators’ (2012) PLoS Medicine 9(4).
35 EMA, ‘European Medicines Agency policy on publication of
clinical data for medicinal products for human use, POLI-
CY/0070’ (October 2014) EMA/240810/2013, 4.1.
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ments towards publication seems to be running into
a deadlock. In the end, only time can tell whether the
clinical trial data transparency actually impedes in-
novation by preventing companies from reaping the
benefits of their investments, or if it actually fosters
innovation by granting easier access to clinical trials
data to inspire the development of novel products. It
remains to been seen if the costs involved by the pub-
lication and redaction process incurred by both the
industry and theAgencywill pay off in termsof gains
in public health.
However, the EMA, the EU legislator and now al-
so the General Court have made a normative choice
in favor of transparency. The Court’s vision of the un-
derlying normative reasoning in favor of transparen-
cy becomes clear in the judgements. In the Pari Phar-
ma case the Court states: ‘In the field of medicinal
products, that requirement of transparency is justi-
fied by the need for supervision of the EMA’s activ-
ities and, in particular, by healthcare and research
professionals, (…).’36 Moreover, in the Intervet case
the Court refers to the broader logic of transparency
in EU institutional law: ‘it should be pointed out that
the transparency of the process followed by the EMA
and the possibility to obtain access to the documents
used by that agency’s experts to prepare their scien-
tific assessment contribute to such an authority ac-
quiring greater legitimacy in the eyes of the persons
to whom that measure is addressed and to increas-
ing their confidence in that authority and to ensur-
ing the authority is more accountable to citizens in
a democratic system.’37
So, although the protection of public health
through enabling peer review of published data and
further use of these data to foster health innovation
might be driving forces behind the EMAs ambitious
clinical trials publication policy, transparency is ac-
tually more than that. It is a normative choice that is
enshrined in EU administrative and institutional law
and vigorously promoted by several stakeholders in
the last years. This will be very difficult to argue
against.
In this regard, it is also interesting to note that the
judgements leave the question ofwhat constitutes an
‘overriding public interest’ unanswered. Even if in-
formation is deemed commercially confidential un-
der Article 4(2) of the Transparency Regulation, it
might still be disclosed under an overriding reason
of public interest. It could be argued that even if a
company would pass the hurdle of proving commer-
cial confidentiality under Article 4(2) of the Trans-
parency Regulation, the second limb of that excep-
tion might still lead to publication as the normative
choice in favor of transparency also might lead to a
broadly construed ‘overriding public interest’ and
thus disclosure of commercially sensitive informa-
tion. However, the Court in its access to documents
case law has so far not been very keen on recogniz-
ing an overriding public interest which would allow
for disclosure of information that would otherwise
benefit from a publication exemption.38 For example
in C-612/13P Client Earth, where ClientEarth argued
that the principles of democracy and transparency
would lead to an overriding public interest of citizens
being informed about the compatibility of national
law with EU environmental law, the Court ruled that
‘considerations as general as those relied on by Clien-
tEarth arenot capable of demonstrating that theprin-
ciples of transparency and democracy raised (…) is-
sues of particularly pressing concern which could
have prevailed over the reasons justifying the refusal
to disclose.’ 39
In the cases at hand, as the information was not
deemed commercially sensitive, this clause was not
applicable and the Court only hinted at the fact that
pharmacovigilance could be an overriding public in-
terest for publication.40 The Ombudsman took a
quite strong position on the matter, arguing that ‘…
in relation to the overriding public interest test, (…)
EMA should consider that there is always a com-
pelling reason for information to be disclosed, where
information at issue has clinical value to clinicians
(as regards understanding the safety and efficacy of
a product for uses to which it is put, including off-la-
bel uses). Such information should always be dis-
closed even where disclosure risks undermining a
company’s commercial interests. In short, public
36 Case T-235/15 Pari Pharma GmbH v European Medicines Agency
[2018] ECLI:EU:T:2018:65, para 99.
37 Case T-729/15 MSD Animal Health Innovation GmbH and
Intervet international BV v European Medicines Agency [2018]
ECLI:EU:T:2018:67, para 5.
38 See, D Curtin and P Leino-Sandberg, ‘Openness, Transparency
and the Right of Access to Documents in the EU: In-depth analy-
sis’ (2016) Report for the Petitions Committee, European Parlia-
ment <http://www.europarl.europa.eu/thinktank/en/document
.html?reference=IPOL_IDA(2016)556973> accessed 23 May
2018.
39 Case C-612/13P ClientEarth v European Commission [2015]
ECLI:EU:C:2015:486, para 93.
40 Case T-235/15 Pari Pharma GmbH v European Medicines Agency
[2018] ECLI:EU:T:2018:65, para 101.
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health should always trump commercial interests.’41
It remains to be seen how far the scope of overrid-
ing public interests might reach in the context of
pharmaceutical data. Following these cases, this
question remains ambiguous and in this regard fur-
ther clarification is required.
41 European Ombudsman, ‘Decision on own-initiative inquiry
OI/3/2014/FOR concerning the partial refusal of the European
Medicines Agency to give public access to studies related to the
approval of a medicinal product’ (June 2016) para 74.
